NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 106)
Posted On: 03/16/2018 4:41:35 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Incorporates Australian Subsidiary
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the incorporation of its first Australian wholly owned subsidiary, PreveCeutical (Australia) Pty Ltd. Per the update, the company’s decision to incorporate a subsidiary in Australia was influenced by the nation’s strong foundation of academic and clinical research, as well as the government’s commitment to supporting innovation through a range of programs and incentives. “Establishing a business presence in Australia will allow PreveCeutical to better access expertise and partnerships for its drug development programs,” Dr. Maher Khaled, PreveCeutical’s director of international operations, stated in the news release. “Many specialized Australian hospitals have strong clinical trial capabilities as well as the diverse patient populations needed for the range of products PreveCeutical is currently developing. Combined with Australia’s favourable regulatory regime for clinical trials, these benefits make Australia an attractive location for product development in preparation for commercialisation through the Company’s established North American networks.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the incorporation of its first Australian wholly owned subsidiary, PreveCeutical (Australia) Pty Ltd. Per the update, the company’s decision to incorporate a subsidiary in Australia was influenced by the nation’s strong foundation of academic and clinical research, as well as the government’s commitment to supporting innovation through a range of programs and incentives. “Establishing a business presence in Australia will allow PreveCeutical to better access expertise and partnerships for its drug development programs,” Dr. Maher Khaled, PreveCeutical’s director of international operations, stated in the news release. “Many specialized Australian hospitals have strong clinical trial capabilities as well as the diverse patient populations needed for the range of products PreveCeutical is currently developing. Combined with Australia’s favourable regulatory regime for clinical trials, these benefits make Australia an attractive location for product development in preparation for commercialisation through the Company’s established North American networks.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼